Cardio-renal-metabolic disease in primary care setting.
CVOTs
chronic kidney disease
heart failure
obesity
technology
type 2 diabetes
Journal
Diabetes/metabolism research and reviews
ISSN: 1520-7560
Titre abrégé: Diabetes Metab Res Rev
Pays: England
ID NLM: 100883450
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
revised:
26
09
2023
received:
18
05
2023
accepted:
23
11
2023
medline:
20
12
2023
pubmed:
20
12
2023
entrez:
20
12
2023
Statut:
aheadofprint
Résumé
In the primary care setting providers have more tools available than ever before to impact positively obesity, diabetes, and their complications, such as renal and cardiac diseases. It is important to recognise what is available for treatment taking into account diabetes heterogeneity. For those who develop type 2 diabetes (T2DM), effective treatments are available that for the first time have shown a benefit in reducing mortality and macrovascular complications, in addition to the well-established benefits of glucose control in reducing microvascular complications. Some of the newer medications for treating hyperglycaemia have also a positive impact in reducing heart failure (HF). Technological advances have also contributed to improving the quality of care in patients with diabetes. The use of technology, such as continuous glucose monitoring systems (CGM), has improved significantly glucose and glycated haemoglobin A1c (HbA1c) values, while limiting the frequency of hypoglycaemia. Other technological support derives from the use of predictive algorithms that need to be refined to help predict those subjects who are at great risk of developing the disease and/or its complications, or who may require care by other specialists. In this review we also provide recommendations for the optimal use of the new medications; sodium-glucose co-transporter-2 inhibitors (SGLT2i) and Glucagon-like peptide-receptor agonists 1 (GLP1RA) in the primary care setting considering the relevance of these drugs for the management of T2DM also in its early stage.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3755Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13-27. https://www.nejm.org/doi/10.1056/NEJMoa1614362
Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet. 1997;27(4):325-351. https://doi.org/10.1023/a:1025635913927
Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health. 2022;7(9):e009773. https://doi.org/10.1136/bmjgh-2022-009773
Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776-785. https://doi.org/10.1016/S2213-8587(19)30249-9
Hemmingsson E, Nowicka P, Ulijaszek S, Sørensen TIA. The social origins of obesity within and across generations. Obes Rev. 2023;24(1):e13514. https://doi.org/10.1111/obr.13514
Balakrishnan VS. Europe's obesity burden on the rise: WHO report. Lancet Diabetes Endocrinol. 2022;10(7):488.
Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early control on future complications (the diabetes & aging study). Diabetes Care. 2019;42(3):416-426. https://doi.org/10.2337/dc17-1144
Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. VERIFY study group. Glycemic durability of an early combination therapy with Vildagliptin and Metformin versus sequential Metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519-1529. https://doi.org/10.1016/S0140-6736(19)32131-2
Mosenzon O, Del Prato S, Schechter M, et al. From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):92. https://doi.org/10.1186/s12933-021-01281-y
Palanca A, Castelblanco E, À Betriu, et al. Subclinical atherosclerosis burden predicts cardiovascular events in individuals with diabetes and chronic kidney disease. Cardiovasc Diabetol. 2019;18(1):93. https://doi.org/10.1186/s12933-019-0897-y
Thorn LM, Gordin D, Harjutsalo V, et al. FinnDiane study group. The presence and consequence of nonalbuminuric chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2015;38(11):2128-2133. https://doi.org/10.2337/dc15-0641
Warncke K, Kummer S, Raile K, et al. Frequency and characteristics of MODY 1 (HNF4A mutation) and MODY 5 (HNF1B mutation): analysis from the DPV database. J Clin Endocrinol Metab. 2019;104(3):845-855. https://doi.org/10.1210/jc.2018-01696
Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361-369. https://doi.org/10.1016/S2213-8587(18)30051-2
Nair ATN, Wesolowska-Andersen A, Brorsson C, et al. Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nat Med. 2022;28(5):982-988. https://doi.org/10.1038/s41591-022-01790-7
Wesolowska-Andersen A, Brorsson CA, Bizzotto R, et al. Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: an IMI DIRECT study. IMI DIRECT Consortium. Cell Rep Med. 2022;3(1):100477. https://doi.org/10.1016/j.xcrm.2021.100477
Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662. https://doi.org/10.1016/S2213-8587(21)00203-5
Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. Erratum in: BMJ. 2022 Jan 18;376:o109. https://doi.org/10.1136/bmj.m4573
Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab. 2019;29(5):1028-1044. https://doi.org/10.1016/j.cmet.2019.03.009
Keating ST, Plutzky J, El-Osta A. Epigenetic changes in diabetes and cardiovascular risk. Circ Res. 2016;118(11):1706-1722. https://doi.org/10.1161/CIRCRESAHA.116.306819
Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia. 2022;65(12):2753-2786. https://doi.org/10.1007/s00125-022-05787-2
Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care. 2021;44(10):2231-2237. https://doi.org/10.2337/dc20-2439
Prattichizzo F, de Candia P, De Nigris V, Nicolucci A, Ceriello A. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: systematic review and meta-analyses of trials according to different scenarios. Metabolism. 2020;110:154308. https://doi.org/10.1016/j.metabol.2020.154308
Charles MA, Leslie RD. Diabetes: concepts of β-cell organ dysfunction and failure would lead to earlier diagnoses and prevention. Diabetes. 2021;70(11):2444-2456. https://doi.org/10.2337/dbi21-0012
Intensive blood-glucose control with sulphonylureas or Insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853. https://doi.org/10.1016/S0140-6736(98)07019-6. Erratum in: Lancet 1999 Aug 14;354(9178):602.
Prattichizzo F, Ceriello A. Is time ready for combination therapy at diagnosis of type 2 diabetes? Diab Metab Res Rev. 2021;37(5):e3460. https://doi.org/10.1002/dmrr.3460
Prattichizzo F, La Sala L, Ceriello A. Two drugs are better than one to start T2DM therapy. Nat Rev Endocrinol. 2020;16(1):15-16. https://doi.org/10.1038/s41574-019-0294-3
Prattichizzo F, Ceriello A. Positioning newer drugs in the management of type 2 diabetes. Lancet Diabetes Endocrinol. 2021;9(3):138-139. https://doi.org/10.1016/S2213-8587(21)00022-X
Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. https://doi.org/10.1016/S0140-6736(19)31149-3
Wiviott SD, Raz I, Bonaca MP, et al. DECLARE-TIMI 58 investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357. https://doi.org/10.1056/NEJMoa1812389
Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ. 2021;373:n1091. Erratum in: BMJ. 2022 Apr 28;377:o1080. https://doi.org/10.1136/bmj.n1091
Wanner C, Heerspink HJL, Zinman B, et al. EMPA-REG OUTCOME investigators. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J Am Soc Nephrol. 2018;29(11):2755-2769. https://doi.org/10.1681/ASN.2018010103
Cahn A, Raz I, Leiter LA, et al. Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58. Diabetes Care. 2021;44(5):1159-1167. https://doi.org/10.2337/dc20-2492
de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-3090. https://doi.org/10.2337/dci22-0027
Prattichizzo F, La Sala L, Rydén L, et al. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Eur J Prev Cardiol. 2019;26(2_Suppl):73-80. https://doi.org/10.1177/2047487319880040
Tromp J, Lim SL, Tay WT, et al. ASIAN-HF investigators. Microvascular disease in patients with diabetes with heart failure and reduced ejection versus preserved ejection fraction. Diabetes Care. 2019;42(9):1792-1799. Epub 2019 Jul 10. https://doi.org/10.2337/dc18-2515
Inoue Y, Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of obesity in adults: latest trends. Curr Obes Rep. 2018;7(4):276-288. https://doi.org/10.1007/s13679-018-0317-8
Neeland IJ, Ross R, Després JP, et al. International atherosclerosis society; international chair on cardiometabolic risk working group on visceral obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715-725. https://doi.org/10.1016/S2213-8587(19)30084-1
Klein S, Gastaldelli A, Yki-Järvinen H, Scherer PE. Why does obesity cause diabetes? Cell Metab. 2022;34(1):11-20. https://doi.org/10.1016/j.cmet.2021.12.012
Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978-3989. https://doi.org/10.1172/JCI129186
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-1428. https://doi.org/10.1016/S0140-6736(05)66378-7
Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol. 2022;28(39):5691-5706. https://doi.org/10.3748/wjg.v28.i39.5691
Wenzl FA, Ambrosini S, Mohammed SA, et al. Inflammation in metabolic cardiomyopathy. Front Cardiovasc Med. 2021;8:742178. https://doi.org/10.3389/fcvm.2021.742178
Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology. 2002;123(3):882-932. Erratum in: Gastroenterology 2002 Nov;123(5):1752. https://doi.org/10.1053/gast.2002.35514
Weghuber D, Barrett T, Barrientos-Pérez M, et al. STEP TEENS investigators. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245-2257. https://doi.org/10.1056/NEJMoa2208601
Jastreboff AM, Aronne LJ, Ahmad NN, et al. SURMOUNT-1 investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038
Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56-65. https://doi.org/10.1001/jama.2011.1914
Shah VN, Prattichizzo F, Ceriello A. Obesity and diabetes. Diab Technol Ther. 2023;25(S1):S217-S226. https://doi.org/10.1089/dia.2023.2515
Abdul Wahab R, le Roux CW. A review on the beneficial effects of bariatric surgery in the management of obesity. Expert Rev Endocrinol Metab. 2022;17(5):435-446. https://doi.org/10.1080/17446651.2022.2110865
Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(5):853-872. https://doi.org/10.1002/ejhf.1170
He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996-1002. https://doi.org/10.1001/archinte.161.7.996
Ceriello A, Catrinoiu D, Chandramouli C, et al. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol. 2021;20(1):218. https://doi.org/10.1186/s12933-021-01408-1
Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105-113. https://doi.org/10.1016/S2213-8587(14)70219-0
Targher G, Dauriz M, Laroche C, et al. ESC-HFA HF Long-Term Registry investigators. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(1):54-65. https://doi.org/10.1002/ejhf.679
Dauriz M, Targher G, Laroche C, et al. ESC-HFA heart failure long-term registry. Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA heart failure long-term registry. Diabetes Care. 2017;40(5):671-678. https://doi.org/10.2337/dc16-2016
Dauriz M, Mantovani A, Bonapace S, et al. Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. Diabetes Care. 2017;40(11):1597-1605. https://doi.org/10.2337/dc17-0697
Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138(9):861-870. https://doi.org/10.1161/CIRCULATIONAHA.118.034646
Sepehrvand N, Alemayehu W, Dyck GJB, et al. External validation of the H2F-PEF model in diagnosing patients with heart failure and preserved ejection fraction. Circulation. 2019;139(20):2377-2379. https://doi.org/10.1161/CIRCULATIONAHA.118.038594
Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(10):1169-1186. https://doi.org/10.1002/ejhf.1531
Zinman B, Lachin JM, Inzucchi SE, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. https://doi.org/10.1056/NEJMoa1504720
Neal B, Perkovic V, Mahaffey KW, et al. CANVAS program collaborative group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. https://doi.org/10.1056/NEJMoa1611925
Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with Ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425-1435. https://doi.org/10.1056/NEJMoa2004967
Perkovic V, Jardine MJ, Neal B, et al. CREDENCE trial investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306. https://doi.org/10.1056/NEJMoa1811744
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446. https://doi.org/10.1056/NEJMoa2024816
Bhatt DL, Szarek M, Pitt B, et al. SCORED investigators. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129-139. https://doi.org/10.1056/NEJMoa2030186
McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148-158. https://doi.org/10.1001/jamacardio.2020.4511
Yusuf S, Ostergren JB, Gerstein HC, et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation. 2005;112(1):48-53. https://doi.org/10.1161/CIRCULATIONAHA.104.528166
Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Studies of Left Ventricular Dysfunction. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107(9):1291-1296. https://doi.org/10.1161/01.cir.0000054611.89228.92
Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on Glycemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333-340. https://doi.org/10.1016/S2213-8587(17)30087-6
Wijkman MO, Claggett B, Vaduganathan M, et al. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022;21(1):110. https://doi.org/10.1186/s12933-022-01545-1
Inzucchi SE, Docherty KF, Køber L, et al. DAPA-HF investigators and committees. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care. 2021;44(2):586-594. https://doi.org/10.2337/dc20-1675
Seferović PM, Fragasso G, Petrie M, et al. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure. Eur J Heart Fail. 2020;22(11):1984-1986. https://doi.org/10.1002/ejhf.2026
McMurray JJV, DeMets DL, Inzucchi SE, et al. DAPA-HF committees and investigators. The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail. 2019;21(11):1402-1411. https://doi.org/10.1002/ejhf.1548
Packer M, Anker SD, Butler J, et al. EMPEROR-reduced trial investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. https://doi.org/10.1056/NEJMoa2022190
Solomon SD, McMurray JJV, Claggett B, et al. DELIVER trial committees and investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. https://doi.org/10.1056/NEJMoa2206286
Anker SD, Butler J, Filippatos G, et al. EMPEROR-preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. https://doi.org/10.1056/NEJMoa2107038
Bhatt DL, Szarek M, Steg PG, et al. SOLOIST-WHF trial investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117-128. https://doi.org/10.1056/NEJMoa2030183
Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor Empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. https://doi.org/10.1038/s41591-021-01659-1
Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757-767. https://doi.org/10.1016/S0140-6736(22)01429-5
Margulies KB, Hernandez AF, Redfield MM, et al. NHLBI heart failure clinical research network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500-508. https://doi.org/10.1001/jama.2016.10260
Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69-77. https://doi.org/10.1002/ejhf.657
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. STEP-HFpEF trial committees and investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023. https://doi.org/10.1056/NEJMoa2306963
Gerstein HC, Swedberg K, Carlsson J, et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008;168(15):1699-1704. https://doi.org/10.1001/archinte.168.15.1699
Goode KM, John J, Rigby AS, et al. Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart. 2009;95(11):917-923. https://doi.org/10.1136/hrt.2008.156646
Castagno D, Baird-Gunning J, Jhund PS, et al. Intensive control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J. 2011;162(5):938-948.e2. https://doi.org/10.1016/j.ahj.2011.07.030
Lawson CA, Jones PW, Teece L, et al. Association between type 2 diabetes and all-cause hospitalization and mortality in the UK general heart failure population: stratification by diabetic control and medication intensification. JACC Heart Fail. 2018;6(1):18-26. https://doi.org/10.1016/j.jchf.2017.08.020
Lee AK, Warren B, Lee CJ, et al. The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care. 2018;41(1):104-111. https://doi.org/10.2337/dc17-1669
Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010;33(6):1389-1394. https://doi.org/10.2337/dc09-2082
Seferović PM, Coats AJS, Ponikowski P, et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. 2020;22(2):196-213. https://doi.org/10.1002/ejhf.1673
Kernan WN, Viscoli CM, Furie KL, et al. IRIS trial investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321-1331. https://doi.org/10.1056/NEJMoa1506930
Erdmann E, Charbonnel B, Wilcox RG, et al. PROactive Investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30(11):2773-2778. https://doi.org/10.2337/dc07-0717
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135. https://doi.org/10.1016/S0140-6736(09)60953-3
Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):ehad192-4140. https://doi.org/10.1093/eurheartj/ehad192
Scirica BM, Braunwald E, Raz I, et al. SAVOR-TIMI 53 Steering Committee and Investigators*. Heart failure, Saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579-1588. https://doi.org/10.1161/CIRCULATIONAHA.114.010389
Zannad F, Cannon CP, Cushman WC, et al. EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking Alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-2076. https://doi.org/10.1016/S0140-6736(14)62225-X
McMurray JJV, Ponikowski P, Bolli GB, et al. VIVIDD trial committees and investigators. Effects of Vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail. 2018;6(1):8-17. https://doi.org/10.1016/j.jchf.2017.08.004
Standl E. GLP-1 receptor agonists and cardiovascular outcomes: an updated synthesis. Lancet Diabetes Endocrinol. 2019;7(10):741-743. Epub 2019 Aug 14. PMID: 31422061. https://doi.org/10.1016/S2213-8587(19)30267-0
Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018. https://doi.org/10.1038/nrdp.2015.18
Saran R, Robinson B, Abbott KC, et al. US renal data system 2018 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2019;73(3 (Suppl 1)):A7-A8. https://doi.org/10.1053/j.ajkd.2019.01.001
Merel E, Denig P, de Zeeuw D, Voorham J, Lambers Heerspink HJ. Hellemons, Petra Denig, Dick de Zeeuw, et al. Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort. Nephrol Dial Transplant. 2013;28(Issue 3):706-715. https://doi.org/10.1093/ndt/gfs567
Assogba GF, Couchoud C, Roudier C, et al. Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: the ENTRED surveys (2001 and 2007). Diabetes Metab. 2012;38(6):558-566. https://doi.org/10.1016/j.diabet.2012.08.004
NHS Digital. National Diabetes Audit - 2015-2016. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-2015-2016-report-1-care-processes-and-treatment-targets
American diabetes association. Diabetes Care 2022. https://doi.org/10.2337/dc22-Sint
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. Erratum in: Eur Heart J. 2020 Dec 1;41(45):4317. https://doi.org/10.1093/eurheartj/ehz486
Kidney disease improving global outcomes. Kidney Int 2022.
Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302-308. https://doi.org/10.1681/ASN.2012070718
Ninomiya T, Perkovic V, de Galan BE, et al. ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813-1821. https://doi.org/10.1681/ASN.2008121270
Rosengren A, Edqvist J, Rawshani A, et al. Excess risk of hospitalisation for heart failure among people with type 2 diabetes. Diabetologia. 2018;61(11):2300-2309. https://doi.org/10.1007/s00125-018-4700-5
Fox CS, Matsushita K, Woodward M, et al. Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662-1673. https://doi.org/10.1016/S0140-6736(12)61350-6
Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311(24):2518-2531. https://doi.org/10.1001/jama.2014.6634
Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52-60. Erratum in: JAMA. 2015 Sep 15;314(11):1179. Leening, Maarten [corrected to Leening, Maarten J G]. https://doi.org/10.1001/jama.2015.7008
IDF Diabetes Atlas, 10th ed. https://diabetesatlas.org/. Diabetes Federation; 2021.
Wen CP, Chang CH, Tsai MK, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 2017;92(2):388-396. https://doi.org/10.1016/j.kint.2017.01.030
United States Renal Data System. Annual data report. Vol 1; 2018:29-44.
Hellemons ME, Denig P, de Zeeuw D, Voorham J, Lambers Heerspink HJ. Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort. Nephrol Dial Transplant. 2013;28(3):706-715. https://doi.org/10.1093/ndt/gfs567
Pongrac-Barlovic D, Groop P.-H. Kidney Disease. Textbook ESC CardioMed. 3rd ed. Oxford University Press; 2018. Chapter 19:11.
Handelsman Y, Anderson JE, Bakris GL, et al. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diab Compl. 2022;36(2):108101. https://doi.org/10.1016/j.jdiacomp.2021.108101
Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American association of clinical endocrinologists and American college of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary. Endocr Pract. 2020;26(10):1196-1224. https://doi.org/10.4158/CS-2020-0490
Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23((Suppl 2)):1-87. https://doi.org/10.4158/EP171764.APPGL
Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. Erratum in: Eur Heart J. 2020 Nov 21;41(44):4255. https://doi.org/10.1093/eurheartj/ehz455
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168-3209. https://doi.org/10.1016/j.jacc.2018.11.002
Schnell O, Standl E, Catrinoiu D, et al. Report from the 4th cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2019;18(1):30. https://doi.org/10.1186/s12933-019-0822-4
Giugliano D, Maiorino MI, Bellastella G, Longo M, Chiodini P, Esposito K. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials. Diab Obes Metab. 2019;21(11):2576-2580. https://doi.org/10.1111/dom.13847
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39. https://doi.org/10.1016/S0140-6736(18)32590-X
Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829. https://doi.org/10.1016/S0140-6736(20)31824-9
Rossing P, Inzucchi SE, Vart P, et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 2022;10(1):24-34. https://doi.org/10.1016/S2213-8587(21)00295-3
Valensi P, Prévost G, Pinto S, Halimi JM, Donal E. The impact of diabetes on heart failure development: the cardio-renal-metabolic connection. Diabetes Res Clin Pract. 2021;175:108831. https://doi.org/10.1016/j.diabres.2021.108831
Birkeland KI, Bodegard J, Eriksson JW, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study. Diabetes Obes Metabol. 2020;22(9):1607-1618. https://doi.org/10.1111/dom.14074
Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int. 2022;102(5):990-999. https://doi.org/10.1016/j.kint.2022.06.013
Valensi P, Picard S, Pathak A. Type 2 diabetes: why should diabetologists and cardiologists work more closely together? Diabetes Metab. 2019;45(6):501-504. https://doi.org/10.1016/j.diabet.2019.07.007
Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study). Circulation. 2018;137(4):323-334. https://doi.org/10.1161/CIRCULATIONAHA.117.032038
Neal B, Perkovic V, Matthews DR, et al. Rationale, design and baseline characteristics of the Canagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diab Obes Metab. 2017;19(3):387-393. https://doi.org/10.1111/dom.12829
McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. https://doi.org/10.1056/NEJMoa1911303
Solomon SD, de Boer RA, DeMets D, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021;23(7):1217-1225. https://doi.org/10.1002/ejhf.2249
Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139(11):1384-1395. https://doi.org/10.1161/CIRCULATIONAHA.118.037778
Herrington WG, Staplin N, Wanner C, et al. The EMPA-KIDNEY collaborative group; empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127. https://doi.org/10.1056/NEJMoa2204233
Masmiquel L, Leiter LA, Vidal J, et al. Leader 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovasc Diabetol. 2016;15(1):29. https://doi.org/10.1186/s12933-016-0341-5
Leiter LA, Bain SC, Hramiak I, et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18(1):73. https://doi.org/10.1186/s12933-019-0871-8
Husain M, Birkenfeld AL, Donsmark M, et al. PIONEER 6 investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-851. https://doi.org/10.1056/NEJMoa1901118
Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Trial Investigators. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of Dulaglutide. Diab Obes Metab. 2018;20(1):42-49. https://doi.org/10.1111/dom.13028
Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228-1239. https://doi.org/10.1056/NEJMoa1612917
Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591-598. https://doi.org/10.1038/s41591-022-01707-4
Nissen SE, Lincoff AM, Brennan D, et al. For the CLEAR outcomes investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353-1364. https://doi.org/10.1056/NEJMoa2215024
Buse J, Rosenstock J, Sesti G, et al. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47. https://doi.org/10.1016/S0140-6736(09)60659-0
Wilding JPH, Batterham RL, Calanna S, et al. STEP 1 study group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183
Dungan KM, Povedano ST, Forst T, et al. Once-weekly Dulaglutide versus once-daily Liraglutide in Metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349-1357. https://doi.org/10.1016/S0140-6736(14)60976-4
Frías JP, Davies MJ, Rosenstock J, et al. SURPASS-2 investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519
Harrington J, Udell JA, Jones WS, et al. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. Am Heart J. 2022;253:86-98. https://doi.org/10.1016/j.ahj.2022.05.010
Min T, Bain SC. The role of Tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diab Ther. 2021;12(1):143-157. https://doi.org/10.1007/s13300-020-00981-0
McGuire DK, Busui RP, Deanfield J, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metabol. 2023;25(7):1932-1941. https://doi.org/10.1111/dom.15058
Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61-69. https://doi.org/10.1016/j.ahj.2020.07.008
Amiel SA. The consequences of hypoglycemia. Diabetologia. 2021;64(5):963-970. https://doi.org/10.1007/s00125-020-05366-3
Heller SR, Geybels MS, Iqbal A, Liu L, Wagner L, Chow E. A higher non-severe hypoglycemia rate is associated with an increased risk of subsequent severe hypoglycemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study. Diabetologia. 2022;65(1):55-64. https://doi.org/10.1007/s00125-021-05556-7
Standl E, Stevens SR, Armstrong PW, et al. TECOS study group. Increased risk of severe Hypo events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype. Diabetes Care. 2018;41(3):596-603. https://doi.org/10.2337/dc17-1778
Standl E, Stevens SR, Lokhnygina Y, et al. EXSCEL study group. Confirming the bidirectional nature of the association between severe Hypo and cardiovascular events in type 2 diabetes: insights from EXSCEL. Diabetes Care. 2020;43(3):643-652. https://doi.org/10.2337/dc19-1079
Sinclair AJ, Pennells D, Abdelhafiz AH HypoGlycemic therapy in frail older people with type 2 diabetes mellitus-a choice determined by metabolic phenotype. Aging Clin Exp Res. 2022;34(9):1949-1967. https://doi.org/10.1007/s40520-022-02142-8
Rydén L, Standl E. After Metformin - next steps for type 2 diabetes with low cardiovascular risk. N Engl J Med. 2022;387(12):1136-1138. https://doi.org/10.1056/NEJMe2210531
Kristófi R, Bodegard J, Norhammar A, et al. Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes: a two-country nationwide observational study. Diabetes Care. 2021;44(5):1211-1218. https://doi.org/10.2337/dc20-2839
DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391(10138):2449-2462. https://doi.org/10.1016/S0140-6736(18)31320-5
Rawshani A, Rawshani A, Franzen S, et al. Range of risk factor levels: control, mortality, and cardiovascular outcomes in type 1 diabetes mellitus. Circulation. 2017;135(16):1522-1531. https://doi.org/10.1161/CIRCULATIONAHA.116.025961
Ceriello A, Prattichizzo F, Phillip M, Hirsch IB, Mathieu C, Battelino T. Glycemic management in diabetes: old and new approaches. Lancet Diabetes Endocrinol. 2022;10(1):75-84. https://doi.org/10.1016/S2213-8587(21)00245-X
Welters A, Tittel SR, Laubner K, et al. Long-term trends of BMI and cardiometabolic risk factors among adults with type 1 diabetes: an observational study from the German/Austrian DPV registry. Diabetes Res Clin Pract. 2021;178:108973. https://doi.org/10.1016/j.diabres.2021.108973
Braffett BH, Bebu I, El Ghormli L, et al. DCCT/EDIC research group. Cardiometabolic risk factors and incident cardiovascular disease events in women vs men with type 1 diabetes. JAMA Netw Open. 2022;5(9):e2230710. https://doi.org/10.1001/jamanetworkopen.2022.30710
Anson M, Zhao SS, Austin P, Ibarburu GH, Malik RA, Alam U. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study. Diabetologia. 2023;66(10):1869-1881. https://doi.org/10.1007/s00125-023-05975-8
Palanca A, van Nes F, Pardo F, Ampudia Blasco FJ, Mathieu C. Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with type 1 diabetes: a European two-center experience. Diabetes Care. 2022;45(3):650-658. https://doi.org/10.2337/dc21-1584
Dejgaard TF, von Scholten BJ, Christiansen E, et al. ADJUNCT ONE and ADJUNCT TWO Investigators. Efficacy and safety of Liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. Diab Obes Metab. 2021;23(12):2752-2762. https://doi.org/10.1111/dom.14532
Martens T, Beck RW, Bailey R, et al. MOBILE study group. Effect of continuous glucose monitoring on control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021;325(22):2262-2272. https://doi.org/10.1001/jama.2021.7444
Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603. https://doi.org/10.2337/dci19-0028
Grady M, Cameron H, Bhatiker A, Holt E, Schnell O. Real-world evidence of improved control in people with diabetes using a bluetooth-connected blood glucose meter with a mobile diabetes management App. Diab Technol Ther. 2022;24(10):770-778. https://doi.org/10.1089/dia.2022.0134
Longo RR, Elias H, Khan M, Seley JJ. Use and accuracy of inpatient CGM during the COVID-19 pandemic: an observational study of general medicine and ICU patients. J Diabetes Sci Technol. 2022;16(5):1136-1143. https://doi.org/10.1177/19322968211008446
Buschur EO, Faulds E, Dungan K CGM in the hospital: is it ready for prime time? Curr Diab Rep. 2022;22(9):451-460. https://doi.org/10.1007/s11892-022-01484-x
Galindo RJ, Aleppo G, Klonoff DC, et al. Implementation of continuous glucose monitoring in the hospital: emergent considerations for remote glucose monitoring during the COVID-19 pandemic. J Diabetes Sci Technol. 2020;14(4):822-832. https://doi.org/10.1177/1932296820932903
American Diabetes Association Professional Practice Committee. 7. Diabetes technology: standards of medical care in diabetes-2022. Diabetes Care. 2022;45((Suppl 1)):S97-S112. https://doi.org/10.2337/dc22-S007
Grace T, Salyer J. Use of real-time continuous glucose monitoring improves control and other clinical outcomes in type 2 diabetes patients treated with less intensive therapy. Diab Technol Ther. 2022;24(1):26-31. https://doi.org/10.1089/dia.2021.0212
Battelino T, Alexander CM, Amiel SA, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2023;11(1):42-57. https://doi.org/10.1016/S2213-8587(22)00319-9
Berkelmans GFN, Gudbjörnsdottir S, Visseren FLJ, et al. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus. Eur Heart J. 2019;40(34):2899-2906. https://doi.org/10.1093/eurheartj/ehy839
Dziopa K, Asselbergs FW, Gratton J, Chaturvedi N, Schmidt AF. Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings. Diabetologia. 2022;65(4):644-656. https://doi.org/10.1007/s00125-021-05640-y
Conroy RM, Pyörälä K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003. https://doi.org/10.1016/s0195-668x(03)00114-3
Stevens RJ, Kothari V, Adler AI, Stratton IM. United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 2001;101(6):671-679. Erratum in: Clin Sci (Lond) 2002 Jun;102(6):679. https://doi.org/10.1042/cs20000335
Nicolucci A, Romeo L, Bernardini M, et al. Prediction of complications of type 2 Diabetes: a Machine learning approach. Diabetes Res Clin Pract. 2022;190:110013. https://doi.org/10.1016/j.diabres.2022.110013
Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541-551. https://doi.org/10.1016/S0140-6736(17)33102-1
Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279-1290. Retraction in: N Engl J Med. 2018 Jun 21;378(25):2441-2442. Erratum in: N Engl J Med. 2014 Feb 27;370(9):886. Corrected and republished in: N Engl J Med. 2018 Jun 21;378(25):e34. Epub 2013 Feb 25. https://doi.org/10.1056/NEJMoa1200303
Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al. CORDIOPREV Investigators. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet. 2022;399(10338):1876-1885. https://doi.org/10.1016/S0140-6736(22)00122-2
Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the women's health initiative randomized controlled dietary modification trial. JAMA. 2006;295(6):655-666. https://doi.org/10.1001/jama.295.6.655
Lindström J, Louheranta A, Mannelin M, et al. Finnish diabetes prevention study group. The Finnish diabetes prevention study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26(12):3230-3236. https://doi.org/10.2337/diacare.26.12.3230
Lindström J, Peltonen M, Eriksson JG, et al. High-fibre, low-fat diet predicts long-term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia. 2006;49(5):912-920. https://doi.org/10.1007/s00125-006-0198-3
Sluik D, Buijsse B, Muckelbauer R, et al. Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis. Arch Intern Med. 2012;172(17):1285-1295. https://doi.org/10.1001/archinternmed.2012.3130
Wahid A, Manek N, Nichols M, et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. J Am Heart Assoc. 2016;5(9):e002495. https://doi.org/10.1161/JAHA.115.002495
American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26(12):3333-3341. https://doi.org/10.2337/diacare.26.12.3333